[The main results of clinical trials of the efficacy, safety and pharmacokinetics of the perspective anti-tuberculosis drug makozinone (PBTZ169)].

Mariandyshev, A O; Khokhlov, A L; Smerdin, S V; Shcherbakova, V S; Igumnova, O V; Ozerova, I V; Bolgarina, A A; Nikitina, N A

Mariandyshev, A O; Khokhlov, A L; Smerdin, S V; Shcherbakova, V S; Igumnova, O V; Ozerova, I V; Bolgarina, A A; Nikitina, N A.

Affiliation

Mariandyshev AO; Northern State Medical University.
Khokhlov AL; Yaroslavl State Medical University.
Smerdin SV; Moscow Regional Clinical Tuberculosis Dispensary.
Shcherbakova VS; NEARMEDIC PHARMA ltd.
Igumnova OV; NEARMEDIC PHARMA ltd.
Ozerova IV; Zakusov Research Institute of Pharmacology.
Bolgarina AA; NEARMEDIC PHARMA ltd.
Nikitina NA; NEARMEDIC PHARMA ltd.

Ter Arkh ; 92(3): 61-72, 2020 Apr 27.

Article in Ru | MEDLINE | ID: mdl-32598795

Subject(s)
Key words

DprE1; DprE1 inhibitors; PBTZ169; benzothiazinones; extensively drug-resistant tuberculosis; isoniazid; macozinone; multidrug-resistant tuberculosis; new antituberculosis drugs; tuberculosis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tuberculosis / Pharmaceutical Preparations Limits: Humans Country/Region as subject: Asia / Europa Language: Ru Journal: Ter Arkh Year: 2020 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google